Inborn errors of immunity-recent advances in research on the pathogenesis
- PMID: 33766139
- PMCID: PMC7992775
- DOI: 10.1186/s41232-021-00159-6
Inborn errors of immunity-recent advances in research on the pathogenesis
Abstract
Primary immunodeficiency (PID) is a genetic disorder with a defect of one of the important components of our immune system. Classical PID has been recognized as a disorder with loss of function of the immune system. Recent studies have unveiled disorders with immune dysfunction with autoimmunity, autoinflammation, allergy, or predisposition to malignancy. Some of them were caused by an augmented immune function or a defect in immune regulation. With this background, the term inborn errors of immunity (IEI) is now used to refer to PID in the International Union of Immunological Societies (IUIS) classification. More than 400 responsible genes have been identified in patients with IEI so far, and importantly, many of them identified lately were caused by a heterologous mutation. Moreover, the onset is not necessarily in childhood, and we started seeing more and more IEI patients diagnosed in adulthood in the clinical settings. Recent advances in genetic analysis, including whole-exome analysis, whole-genome analysis, and RNA-seq have contributed to the identification of the disease-causing gene mutation. We also started to find heterogeneity of phenotype even in the patients with the same mutation in the same family, leading us to wonder if modifier gene or epigenetic modification is involved in the pathogenesis. In contrast, we accumulated many cases suggesting genetic heterogeneity is associated with phenotypic homogeneity. It has thus become difficult to deduce a responsible gene only from the phenotype in a certain type of IEI. Current curative therapy for IEI includes hematopoietic cell transplantation and gene therapy. Other curative therapeutic modalities have been long waited and are to be introduced in the future. These include a small molecule that inhibits the gain-of-function of the molecule- and genome-editing technology. Research on IEI will surely lead to a better understanding of other immune-related disorders including rheumatic diseases and atopic disorders.
Keywords: Functional validation; Inborn errors of immunity; Next-generation sequencing.
Conflict of interest statement
The authors declare they have no competing interests.
Similar articles
-
Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification.J Clin Immunol. 2020 Jan;40(1):66-81. doi: 10.1007/s10875-020-00758-x. Epub 2020 Feb 11. J Clin Immunol. 2020. PMID: 32048120 Free PMC article.
-
Future of Therapy for Inborn Errors of Immunity.Clin Rev Allergy Immunol. 2022 Aug;63(1):75-89. doi: 10.1007/s12016-021-08916-8. Epub 2022 Jan 12. Clin Rev Allergy Immunol. 2022. PMID: 35020169 Free PMC article. Review.
-
Genetic screening in a Brazilian cohort with inborn errors of immunity.BMC Genom Data. 2023 Aug 17;24(1):47. doi: 10.1186/s12863-023-01148-z. BMC Genom Data. 2023. PMID: 37592284 Free PMC article.
-
Enrichment of Immune Dysregulation Disorders in Adult Patients with Human Inborn Errors of Immunity.J Clin Immunol. 2024 Feb 16;44(3):61. doi: 10.1007/s10875-024-01664-2. J Clin Immunol. 2024. PMID: 38363452 Free PMC article.
-
Approach to genetic diagnosis of inborn errors of immunity through next-generation sequencing.Mol Immunol. 2021 Sep;137:57-66. doi: 10.1016/j.molimm.2021.06.018. Epub 2021 Jun 30. Mol Immunol. 2021. PMID: 34216999 Review.
Cited by
-
Whole-transcriptome sequencing-based concomitant detection of viral and human genetic determinants of cutaneous lesions.JCI Insight. 2022 Apr 22;7(8):e156021. doi: 10.1172/jci.insight.156021. JCI Insight. 2022. PMID: 35316210 Free PMC article.
-
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study.Immunother Adv. 2024 Mar 1;4(1):ltae001. doi: 10.1093/immadv/ltae001. eCollection 2024. Immunother Adv. 2024. PMID: 38511087 Free PMC article.
-
Immunoglobulin therapies for primary immunodeficiency diseases (part 2): considerations for dosing strategies.Immunotherapy. 2024;16(13):895-905. doi: 10.1080/1750743X.2024.2382074. Epub 2024 Sep 26. Immunotherapy. 2024. PMID: 39323406 Free PMC article. Review.
-
fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study.Allergy Asthma Clin Immunol. 2024 Sep 17;20(1):47. doi: 10.1186/s13223-024-00904-9. Allergy Asthma Clin Immunol. 2024. PMID: 39289739 Free PMC article.
-
Case Report: Analysis of Preserved Umbilical Cord Clarified X-Linked Anhidrotic Ectodermal Dysplasia With Immunodeficiency in Deceased, Undiagnosed Uncles.Front Immunol. 2021 Dec 22;12:786164. doi: 10.3389/fimmu.2021.786164. eCollection 2021. Front Immunol. 2021. PMID: 35003103 Free PMC article.
References
-
- Tangye SG, AI-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64. doi: 10.1007/s10875-019-00737-x. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources